Moberg Pharma AB (publ)
STO:MOB

Watchlist Manager
Moberg Pharma AB (publ) Logo
Moberg Pharma AB (publ)
STO:MOB
Watchlist
Price: 18.26 SEK -4.85% Market Closed
Market Cap: 852.6m SEK
Have any thoughts about
Moberg Pharma AB (publ)?
Write Note

Intrinsic Value

MOB's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one MOB stock under the Base Case scenario is 0.61 SEK. Compared to the current market price of 18.26 SEK, Moberg Pharma AB (publ) is Overvalued by 97%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

MOB Intrinsic Value
0.61 SEK
Overvaluation 97%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Moberg Pharma AB (publ)

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for MOB cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about MOB?
Bearish
Neutral
Bullish

Fundamental Analysis

Economic Moat
Moberg Pharma AB (publ)

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Moberg Pharma AB (publ)

Provide an overview of the primary business activities
of Moberg Pharma AB (publ).

What unique competitive advantages
does Moberg Pharma AB (publ) hold over its rivals?

What risks and challenges
does Moberg Pharma AB (publ) face in the near future?

Has there been any significant insider trading activity
in Moberg Pharma AB (publ) recently?

Summarize the latest earnings call
of Moberg Pharma AB (publ).

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Moberg Pharma AB (publ).

Provide P/S
for Moberg Pharma AB (publ).

Provide P/E
for Moberg Pharma AB (publ).

Provide P/OCF
for Moberg Pharma AB (publ).

Provide P/FCFE
for Moberg Pharma AB (publ).

Provide P/B
for Moberg Pharma AB (publ).

Provide EV/S
for Moberg Pharma AB (publ).

Provide EV/GP
for Moberg Pharma AB (publ).

Provide EV/EBITDA
for Moberg Pharma AB (publ).

Provide EV/EBIT
for Moberg Pharma AB (publ).

Provide EV/OCF
for Moberg Pharma AB (publ).

Provide EV/FCFF
for Moberg Pharma AB (publ).

Provide EV/IC
for Moberg Pharma AB (publ).

Show me price targets
for Moberg Pharma AB (publ) made by professional analysts.

What are the Revenue projections
for Moberg Pharma AB (publ)?

How accurate were the past Revenue estimates
for Moberg Pharma AB (publ)?

What are the Net Income projections
for Moberg Pharma AB (publ)?

How accurate were the past Net Income estimates
for Moberg Pharma AB (publ)?

What are the EPS projections
for Moberg Pharma AB (publ)?

How accurate were the past EPS estimates
for Moberg Pharma AB (publ)?

What are the EBIT projections
for Moberg Pharma AB (publ)?

How accurate were the past EBIT estimates
for Moberg Pharma AB (publ)?

Compare the revenue forecasts
for Moberg Pharma AB (publ) with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Moberg Pharma AB (publ) and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Moberg Pharma AB (publ) against its competitors.

Analyze the profit margins
(gross, operating, and net) of Moberg Pharma AB (publ) compared to its peers.

Compare the P/E ratios
of Moberg Pharma AB (publ) against its peers.

Discuss the investment returns and shareholder value creation
comparing Moberg Pharma AB (publ) with its peers.

Analyze the financial leverage
of Moberg Pharma AB (publ) compared to its main competitors.

Show all profitability ratios
for Moberg Pharma AB (publ).

Provide ROE
for Moberg Pharma AB (publ).

Provide ROA
for Moberg Pharma AB (publ).

Provide ROIC
for Moberg Pharma AB (publ).

Provide ROCE
for Moberg Pharma AB (publ).

Provide Gross Margin
for Moberg Pharma AB (publ).

Provide Operating Margin
for Moberg Pharma AB (publ).

Provide Net Margin
for Moberg Pharma AB (publ).

Provide FCF Margin
for Moberg Pharma AB (publ).

Show all solvency ratios
for Moberg Pharma AB (publ).

Provide D/E Ratio
for Moberg Pharma AB (publ).

Provide D/A Ratio
for Moberg Pharma AB (publ).

Provide Interest Coverage Ratio
for Moberg Pharma AB (publ).

Provide Altman Z-Score Ratio
for Moberg Pharma AB (publ).

Provide Quick Ratio
for Moberg Pharma AB (publ).

Provide Current Ratio
for Moberg Pharma AB (publ).

Provide Cash Ratio
for Moberg Pharma AB (publ).

What is the historical Revenue growth
over the last 5 years for Moberg Pharma AB (publ)?

What is the historical Net Income growth
over the last 5 years for Moberg Pharma AB (publ)?

What is the current Free Cash Flow
of Moberg Pharma AB (publ)?

Discuss the annual earnings per share (EPS)
trend over the past five years for Moberg Pharma AB (publ).

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Moberg Pharma AB (publ)

Current Assets 347.9m
Cash & Short-Term Investments 326m
Receivables 16.9m
Other Current Assets 5m
Non-Current Assets 611.7m
PP&E 4.3m
Intangibles 574.8m
Other Non-Current Assets 32.6m
Current Liabilities 27.8m
Other Current Liabilities 27.8m
Non-Current Liabilities 2.7m
Long-Term Debt 2.7m
Efficiency

Earnings Waterfall
Moberg Pharma AB (publ)

Revenue
4.9m SEK
Cost of Revenue
-1.7m SEK
Gross Profit
3.2m SEK
Operating Expenses
-32.1m SEK
Operating Income
-28.9m SEK
Other Expenses
6.1m SEK
Net Income
-22.8m SEK

Free Cash Flow Analysis
Moberg Pharma AB (publ)

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

MOB Profitability Score
Profitability Due Diligence

Moberg Pharma AB (publ)'s profitability score is 34/100. The higher the profitability score, the more profitable the company is.

34/100
Profitability
Score

Moberg Pharma AB (publ)'s profitability score is 34/100. The higher the profitability score, the more profitable the company is.

MOB Solvency Score
Solvency Due Diligence

Moberg Pharma AB (publ)'s solvency score is 87/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Negative Net Debt
87/100
Solvency
Score

Moberg Pharma AB (publ)'s solvency score is 87/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

MOB Price Targets Summary
Moberg Pharma AB (publ)

Wall Street analysts forecast MOB stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for MOB is 19.38 SEK with a low forecast of 19.19 SEK and a high forecast of 19.95 SEK.

Lowest
Price Target
19.19 SEK
5% Upside
Average
Price Target
19.38 SEK
6% Upside
Highest
Price Target
19.95 SEK
9% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for MOB?

Click here to dive deeper.

Dividends

Moberg Pharma AB (publ)
does not pay dividends
Shareholder Yield

Current shareholder yield for MOB is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

MOB Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Profile

Moberg Pharma AB (publ) Logo
Moberg Pharma AB (publ)

Country

Sweden

Industry

Pharmaceuticals

Market Cap

836.9m SEK

Dividend Yield

0%

Description

Moberg Pharma AB is a pharmaceutical company, which engages in the development and commercialization of medical products. The company is headquartered in Bromma, Stockholm. The company went IPO on 2011-05-26. Its product portfolio includes products for the treatment of skin diseases and pain, such as Emtrix/Nalox, for the treatment of nails damaged by fungus or psoriasis; Kerasal, for dry and damaged feet, and Kaprolac, a range of products for several types of skin and scalp problems. Additionally, the Company has two projects in phase II of development, namely MOB-15, for the treatment of nail fungus, and Limtop, for the treatment of actinic keratosis, basalioma and genital warts. The firm collaborates with Meda AB, Menarini Group, Perrigo Company, OzHealth Pharma and Zelmic AB, among others. The company is active in more than 35 countries, and operates, among others, through Alterna LLC. The company also owns three Over-The-Counter (OTC) brands in the United States.

Contact

STOCKHOLM
Bromma
Gustavslundsvagen 42, 5 tr.
+46852230700
www.mobergpharma.se

IPO

2011-05-26

Employees

-

Officers

Chief Executive Officer
Ms. Anna Ljung BA, M.Sc.
Co-Founder
Ms. Marie Moberg
Vice President of Finance
Mr. Mark Beveridge
Head of Pharmaceutical Development & Operations
Dr. Christina Erixon
Chief Scientific Officer
Dr. Amir Tavakkol Ph.D.
Senior Director of Sales & Marketing
Gunilla Wengström
Show More
Chief Medical Officer
Anders Broijersen M.D., Ph.D.
Head of Supply
Mr. Robert Ehrl
Show Less

See Also

Discover More
What is the Intrinsic Value of one MOB stock?

The intrinsic value of one MOB stock under the Base Case scenario is 0.61 SEK.

Is MOB stock undervalued or overvalued?

Compared to the current market price of 18.26 SEK, Moberg Pharma AB (publ) is Overvalued by 97%.

Back to Top